REMARKS/ARGUMENTS

I. Claim Status

Claims 1-8 are pending in the instant application. Claims 1 and 5-7 are withdrawn.

II. Restriction/Election

A. Restriction

Claims 1-8 were subject to a requirement for restriction as follows:

- I. Claim 1, IN PART, drawn to a crystal form of 2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid, wherein the said salt is not embraced in the salts described in claims 2 and 3, classified in class 562, subclass 460.
- II. Claims 1, IN PART, and 2, 3 and 4, drawn to a crystal form of 2-amino-7- (ethanimidoylamino)-2-methylhept-5-enoic acid wherein the said salts are described in claims 2 and 3 and pharmaceutical compositions comprising the same, classified in class 562, subclass 460.
- III. Claims 5-7 drawn to methods for the prophylaxis OR treatment of any clinical condition in a mammal for which an inhibitor of nitric oxide synthase is indicated and method of use of compounds described in claim 1 in the manufacture of medicaments, classified in different classes and subclasses.
- IV. Claim 8, drawn to a synthetic preparation method for preparing compounds described in the said claim in class 562 and subclass 460.

-5-

Application Number 10/646,266 Response to Office Action Dated 9 September 2004

Applicants elect the invention of claims 2-4, group II. Claims 1 and 5-8 are withdrawn. Upon a finding of allowability of claims 2-4, applicants respectfully request rejoinder of claim 8 (synthetic preparation method).

B. Election of Species

Applicants elect the species 2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid, sesquihydrochloride (1.5 HCl) for purposes of examination on the merits.

III. Claim Amendments

Claims 2 and 4 have been amended to reflect the elected species, crystalline 2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid, 1.5 hydrochloride. No new matter is introduced.

If the Examiner believes a telephonic interview with Applicant's representative would aid in the prosecution of this application, he is cordially invited to contact Applicant's representative at the below listed number.

Pharmacia Corporation Corporate Patent Department P.O. Box 1027 Chesterfield, Missouri 63006 Philip B Polster II Reg. No. 43,864 (314) 274-9094

(314) 274-7256 (facsimile)